• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

    9/24/25 7:00:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FGEN alert in real time by email
    • FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting
    • FG-3180 to be evaluated in the Phase 2 trial as a companion PET imaging agent and a potential predictive patient selection biomarker
    • Interim analysis expected in 2H 2026



    SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46-expressing cancer lesions in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial will also assess the diagnostic and predictive performance of FG-3180, a companion PET imaging agent, which shares the same CD46-targeted antibody used in FG-3246. The ability of FG-3180 to identify mCRPC lesions and predict response to FG-3246 will be evaluated.

    "With the transformation of FibroGen to a U.S.-focused organization now complete and a robust cash runway into 2028, we are excited to advance our FG-3246 program and initiate the Phase 2 monotherapy trial with the activation of the University of California San Francisco (UCSF) site," said Thane Wettig, Chief Executive Officer of FibroGen. "FG-3246 demonstrated compelling clinical activity in patients that were heavily pre-treated, with a competitive radiographic progression free survival benefit in the Phase 1 monotherapy study. We are confident that the dosing regimen of FG-3246, use of prophylactic G-CSF, and the enrollment of patients in earlier lines of treatment of mCRPC set us up to further demonstrate the potential of this program. We anticipate results from the interim analysis of our Phase 2 study in the second half of 2026. We also look forward to reporting the results from the ongoing investigator-sponsored study of FG-3246 in combination with enzalutamide in the fourth quarter of this year."

    The Phase 2 monotherapy trial (NCT06842498) is a randomized, open label, dose optimization trial designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246 for the treatment of patients with mCRPC who have progressed following ARSI treatment and who have not received chemotherapy for their mCRPC. The trial is scheduled to enroll 75 patients who will be randomized 1:1:1 to receive either 1.8, 2.4 or 2.7 mg/kg AJBW of FG-3246. The primary endpoint of the trial is the determination of the optimal dose for the Phase 3 trial based on efficacy, safety, and PK parameters. Secondary endpoints include radiographic progression free survival (rPFS), prostate-specific antigen (PSA) 50 response, and PSA90 response. An interim analysis is planned once 12 patients enrolled in each of the three dose arms have completed 12 weeks on study or discontinued and is anticipated in the second half of 2026. An exploratory sub-study will evaluate FG-3180, a companion PET imaging agent, as a diagnostic radiopharmaceutical. All patients deemed eligible for participation in the Phase 2 trial will participate in the sub-study evaluating FG-3180 prior to randomization.

    In addition, topline results from the ongoing investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC are expected in the fourth quarter of 2025.

    About FG-3246

    FG-3246 (FOR46) is a potential first-in-class fully human antibody-drug conjugate (ADC), exclusively in-licensed from Fortis Therapeutics, and is being developed by FibroGen for metastatic castration-resistant prostate cancer and potentially other tumor types. FG-3246 binds to an epitope of CD46, a cell receptor target, that induces internalization upon antibody binding, is present at high levels in prostate cancer and other tumor types and demonstrates very limited expression in most normal tissues. FG-3246 is comprised of an anti-CD46 antibody, YS5, linked to the anti-mitotic agent, MMAE, which is a clinically and commercially validated ADC payload. FG-3246 has demonstrated anti-tumor activity in both preclinical and clinical studies.

    FG-3246 is currently in an ongoing Phase 1b/2 study being conducted at UCSF as an investigator-sponsored trial to evaluate FG-3246 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). An additional investigator-sponsored radiopharmaceutical marker trial using a zirconium-89 positron emission tomography (PET) tracer for CD46 that utilizes the YS5 antibody is also underway at UCSF. The Phase 2 monotherapy dose optimization trial for FG-3246 in mCRPC was initiated in the third quarter of 2025, with interim results expected in the second half of 2026. FG-3246 is an investigational drug and not approved for marketing by any regulatory authority.

    About Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Prostate cancer is the second most common malignancy in men, contributing significantly to male mortality rates. Approximately 13% of men will be diagnosed with prostate cancer at some point during their lifetime. There are about 65,000 drug treatable mCRPC cases in the U.S. annually and 5-year survival in mCRPC is approximately 30%.

    About FibroGen

    FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZOTM) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding FibroGen's strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its collaboration partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of FibroGen products and product candidates, statements regarding FibroGen's cash runway, and statements about FibroGen's plans and objectives. These forward-looking statements are typically identified by use of terms such as "may," "will", "should," "on track," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. FibroGen's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

    For Investor Inquiries:

    David DeLucia, CFA

    Senior Vice President and Chief Financial Officer

    [email protected]



    Primary Logo

    Get the next $FGEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FGEN

    DatePrice TargetRatingAnalyst
    8/8/2023$4.00 → $2.00Neutral → Underperform
    BofA Securities
    6/26/2023Buy → Hold
    Stifel
    6/26/2023Buy → Neutral
    BofA Securities
    6/26/2023Outperform → Mkt Perform
    Raymond James
    6/26/2023Outperform → Mkt Perform
    William Blair
    6/2/2023$23.00 → $32.00Hold → Buy
    Stifel
    1/31/2023Mkt Perform → Outperform
    William Blair
    1/26/2023$35.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $FGEN
    SEC Filings

    View All

    FibroGen Inc filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K - FIBROGEN INC (0000921299) (Filer)

    9/5/25 5:04:36 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - FIBROGEN INC (0000921299) (Filer)

    9/2/25 8:00:29 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - FIBROGEN INC (0000921299) (Filer)

    8/18/25 8:45:29 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Delucia David covered exercise/tax liability with 104 shares, decreasing direct ownership by 2% to 4,541 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    9/9/25 7:26:15 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane covered exercise/tax liability with 494 shares, decreasing direct ownership by 2% to 21,239 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    9/9/25 7:25:14 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schoeneck James A bought $119,485 worth of shares (23,567 units at $5.07) (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    7/2/25 4:33:27 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schoeneck James A bought $119,485 worth of shares (23,567 units at $5.07) (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    7/2/25 4:33:27 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane bought $50,663 worth of shares (145,000 units at $0.35), increasing direct ownership by 36% to 543,329 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    3/25/25 9:00:05 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schoeneck James A bought $105,040 worth of shares (300,000 units at $0.35) (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    3/24/25 9:00:05 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    FibroGen downgraded by BofA Securities with a new price target

    BofA Securities downgraded FibroGen from Neutral to Underperform and set a new price target of $2.00 from $4.00 previously

    8/8/23 6:27:35 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen downgraded by Stifel

    Stifel downgraded FibroGen from Buy to Hold

    6/26/23 1:22:02 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen downgraded by BofA Securities

    BofA Securities downgraded FibroGen from Buy to Neutral

    6/26/23 1:16:35 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

    FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to be evaluated in the Phase 2 trial as a companion PET imaging agent and a potential predictive patient selection biomarker Interim analysis expected in 2H 2026 SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46-expressing cancer lesions in patients with metastatic castration-r

    9/24/25 7:00:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

    Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidanceSuccessfully repaid term loan to Morgan Stanley Tactical Value, further simplifying the Company's capital structurePhase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) remains on track to begin in 3Q 2025Cash runway extended into 2028 SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced it has completed the sale of its China subsidiary to AstraZeneca for a total consideration of approximately $220 million, consisting of $85 million in enterprise value and approximate

    9/2/25 7:00:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

    SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 9 at 12:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available here. FibroGen's management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. A replay of the presentation will be posted, whe

    8/27/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Leadership Updates

    Live Leadership Updates

    View All

    FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

    SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. "Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board," said James Schoeneck, chairman of the board of directors of FibroGen. "His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael's deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers." "FibroGen has differentiated potential first-in-class assets and

    6/9/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Appoints David DeLucia as Chief Financial Officer

    SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen's global finance organization. He has most recently served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury. "Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabili

    12/16/24 8:05:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

    SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. "Deyaa's leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need," said Thane Wettig, Chief Executive Officer of FibroGen. "We are excited to welcome him

    3/11/24 7:00:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Financials

    Live finance-specific insights

    View All

    FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

    Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2028 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025 Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for a pivotal Phase 3 trial for roxadustat f

    8/11/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen to Report Second Quarter 2025 Financial Results

    SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call b

    8/4/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

    Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2H 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025 Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients

    5/12/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/14/24 4:52:23 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/12/24 4:01:23 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/12/24 2:33:26 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care